Interestingly, the CBR at week 24 was increased in patients with CPS ≥1 tumor (58.3% vs. 38.1%, two-sided p = 0.066, Supplementary Fig. 8a), and although this benefit was not significant, a longer PFS was observed in this subgroup (median PFS 13.5 vs. 5.4 months in PD-L1 CPS ≥ 1 and <1, respectively, p = 0.0004; two-sided log-rank test, Fig. 5d). This evidence concerns the gene CD274 and neoplasm.